1. Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL

3. Content Outline

4. Stakeholders in Managing Adverse Events of CLL Therapies

5. Concerning Specific Toxicities of Ibrutinib

6. Managing Infections While on Ibrutinib

7. Other Ibrutinib-Related Side Effects

8. When to Substitute Acalabrutinib

9. Headaches Are a Specific Concern for Patients on Acalabrutinib

10. Strategies to Enhance Treatment Adherence

11. Role of PI3K Inhibitors in CLL With Progression

12. Keys for Effective PI3K Inhibitor Use

13. Emerging Role of Venetoclax in CLL Therapy

14. Other Venetoclax-Associated Adverse Events

15. Managing Venetoclax-Associated Neutropenia

16. Concluding Remarks

17. Abbreviations

18. Abbreviations (cont)